Amerikanische Gesellschaft für Hirudotherapie

The efficacy of arterial only microsurgical nasal replantation: a systematic review

Secanho MS, Rajaram R, de Menezes Neto BF, Cavale N, Ng SK, Neto AAP (2024) · ANZ Journal of Surgery · n=29

RCT evidence detailTrial reference
GRADE LowCohort / case series
Sample size of this trial compared with other venous-congestion-flap trialsMarquard JM 20251215Bishop JL 2023843Doğan S 2024570Troeltzsch M 2016330Kucur C 2015260Wang ZD 2022210Lehnhardt M 202196Kruer RM 201459Mozafari N 201056Secanho MS 202429
This trial (highlighted) by sample size alongside other indexed venous-congestion-flap trials. Larger trials generally carry more statistical weight.

Study Profile

Design
systematic review of 27 published reports (29 patients) of microsurgical nasal replantation following traumatic amputation, with comparative analysis of arterial-only versus arterial-and-venous anastomosis approaches; Medline, Scopus, and Embase searches through November 2023; JBI Critical Appraisal Checklist for risk-of-bias assessment (Sao Paulo State University, Botucatu Medical School, Brazil; Austin Health, Heidelberg, Victoria, Australia; King's College Hospital and Guy's and St. Thomas Hospital, London, UK)
Sample size (n)
29
Intervention
Pooled descriptive analysis of nasal replantation outcomes by anastomosis technique: arterial-only versus arterial-and-venous; medicinal leech therapy use, heparin use, complications, tissue preservation, hospital stay, and follow-up outcomes compared between groups
Comparator
Direct comparison of arterial-only versus arterial-and-venous nasal replantation outcomes from the published literature
Primary endpoint
Comparative efficacy and safety of arterial-only versus arterial-and-venous microsurgical nasal replantation, including tissue preservation, complications, hospital stay, and reliance on adjunctive leech/heparin therapy
Primary result
Arterial-only anastomosis was on average 2 hours 32 minutes faster than arterial-and-venous anastomosis; arterial-only cases used medicinal leech therapy significantly more frequently (p=0.01) while arterial-and-venous cases used heparin more frequently (p=0.01); complications, tissue preservation, hospital stay, and follow-up outcomes were otherwise similar between groups; authors concluded that arterial-only anastomosis is a safe and viable approach for nasal replantation
Follow-up duration
follow-up varied by included study (most reported acute postoperative status)

Key Findings

  • First systematic review comparing arterial-only versus arterial-and-venous nasal replantation
  • Arterial-only approach significantly more often required medicinal leech therapy (p=0.01) for venous congestion management
  • Tissue preservation, hospital stay, and follow-up outcomes were comparable between approaches
  • Arterial-only approach was 2.5 hours faster on average — practical advantage in emergency reconstruction
  • Strengthens the broader literature on arterial-only microsurgical replantation supported by adjunctive leech therapy (ear, finger, nose)

Limitations

  • Very small total sample (n=29 patients across 27 studies) - insufficient statistical power for many comparisons
  • All included studies were case reports or small series — risk of selection and publication bias high
  • Heterogeneous nasal amputation mechanisms (assault, animal bite, motor vehicle accident) - confounding likely
  • No randomized comparator design — comparisons rely on pooled descriptive statistics
  • Outcome adjudication varied by included study — no centralized review

Clinical Implications

Secanho 2024 is the first systematic review of nasal microsurgical replantation comparing arterial-only and arterial-and-venous approaches. For US clinicians performing emergency nasal replantation under the K040187-cleared microsurgical-salvage indication, the trial establishes that arterial-only replantation supported by medicinal leech therapy is a safe and time-saving alternative when no suitable vein is available for anastomosis. The trial parallels the ear-replant literature (Facchin 2018, Pertea 2021) in demonstrating that leech therapy enables successful single-vessel microsurgical replantation across multiple anatomic sites.

Related Trials

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.